NIVF Forecast · Updated October 14, 2026
NIVF Stock Forecast: $3–$5 Post-Split Bull Case by December 2026
An independent, speculative $3–$5 post-split scenario for NewGenIvf Group Limited (NASDAQ: NIVF) by December 2026. This is this website's bull case, not a verified Wall Street or Seeking Alpha expert forecast. It depends on improving results, stronger interest and measurable business wins.
- December bull case
- $3–$5 post-split
- Historical revenue (TTM)
- $4.73M
- Reverse split
- 1-for-4 · October 12
- Projected Class A shares
- ~8.92M post-split
Corporate announcements · checked October 14, 2026
Monday, October 12: NIVF completed a 1-for-4 reverse split
NewGenIvf Group Limited's October 7, 2026 Form 6-K announced a one-for-four reverse stock split effective at 12:01 a.m. ET on Monday, October 12, 2026, with split-adjusted Nasdaq trading beginning that day. Every four existing shares consolidated into one. The ticker remains NIVF; the new Class A CUSIP is G0544E600. Nasdaq confirmed the action in its October 8 corporate-action notice.
The filing projected Class A shares outstanding falling from 35,688,329 to approximately 8,922,083, based on the October 6 share count. Outstanding options, warrants and convertible securities were to be adjusted as described in the filing. A reverse split changes the per-share basis, not the underlying value of the business.
Announcement summary, not a verbatim press release. Read the original October 7 company filing and the Nasdaq split confirmation.
NIVF and K25.ai: AI investment and digital-asset coverage
Tickeron's article, “NIVF vs VCIG: Two Micro-Caps Navigating AI and Digital Asset Shifts,” explores NewGenIvf Group Limited's move into AI and digital assets. NewGen's July 30, 2026 company announcement describes an agreed 13% stake in K25.ai, an AI-powered prediction-market platform, subject to completion of the acquisitions under the applicable share purchase agreements. This is an investment agreement, not confirmation of a completed merger with an AI company. The potential AI exposure adds to the site's growth-catalyst discussion; it does not establish acquired revenue or guarantee the $3–$5 scenario.
Read the Tickeron article: NIVF vs VCIG — AI and digital-asset shifts · Read NewGen's July 30, 2026 K25.ai announcement
Merger announcement: distinguish a proposal from a completed deal
NewGen previously proposed a reverse merger with European Wellness Investment Holdings Limited. Its March 31, 2025 announcement said that proposed transaction had been terminated. A newly completed merger has not been verified in the sources reviewed for this update. The $3–$5 scenario therefore does not assume a completed merger or acquired revenue.
Read NewGenIVF's merger-termination announcement (March 31, 2025).
Method
What could drive the NIVF forecast
NewGenIvf Group Limited combines operating fertility clinics, about $4.73M in trailing revenue in the site's October 1 snapshot and additional interests in property and technology. Through December 2026, stronger clinic activity, quantified contracts, wider market awareness and renewed small-cap interest could all support a higher valuation.
Scenarios
NIVF price prediction scenarios
| December 2026 bull case | Post-split price | What could support it |
|---|---|---|
| Lower end | $3.00 | Improving clinic momentum and renewed visibility among small-cap investors. |
| Midpoint | $4.00 | Revenue growth, stronger trading liquidity and progress across the wider platform. |
| Upper end | $5.00 | Financial disclosures available by December confirm progress, a division signs quantified contracts, and liquidity strengthens. |
Using the filing-projected 8,922,083 post-split Class A shares, $3, $4 and $5 imply approximately $26.77M, $35.69M and $44.61M of Class A equity value, respectively. These are not fully diluted valuations and exclude subsequent issuance. A split alone creates no economic gain. These hypothetical levels are not guaranteed targets or recommendations.
Calendar
Developments to watch through December 2026
- New company financial disclosures that show stronger clinic activity and revenue momentum; no unverified earnings date is assumed.
- Post-split trading updates and new share-count disclosures that establish the latest valuation basis.
- Greater healthcare-sector interest that brings attention to emerging fertility-services companies.
- New business updates across fertility, property or technology could broaden the NewGenIvf growth story.
- Any new strategic transaction supported by a company filing, with announced terms and closing status checked before incorporating it into the scenario.
Read the tape
Two positive signals to watch each week
Read next
More NIVF analysis
NIVF stock price prediction
The six-point bull case and the $3–$5 post-split December scenario.
NewGenIvf Group Limited profile
Clinics, divisions, leadership and financial history.
Is NIVF a good investment?
The positive investment case and the growth drivers behind it.
Penny stocks watchlist
The screening framework and catalyst calendar we apply to NIVF.
Sources & further reading
- Tickeron — NIVF vs VCIG: Two Micro-Caps Navigating AI and Digital Asset Shifts (market commentary)
- NewGen July 30, 2026 announcement — agreed 13% K25.ai stake subject to acquisition completion
- NewGenIvf October 7, 2026 Form 6-K — reverse split and projected Class A share count
- Nasdaq — confirmation of NIVF's October 12, 2026 one-for-four reverse split
- NewGenIVF March 31, 2025 announcement — European Wellness proposed merger terminated
- NewGenIvf Group Limited investor relations — company profile and clinic locations
- Yahoo Finance — NewGenIvf Group Limited (NIVF) quote, price and profile
- CNBC — NIVF quote, key stats, revenue and EBITDA
- StockAnalysis — NewGenIvf Group (NIVF) market cap, shares outstanding, earnings date
- Finviz — NIVF market cap, float, insider ownership, offering news
- TipRanks — 3 Penny Stocks on Investors' Radar, October 1
- MarketBeat — Penny Stocks List, most active shares under $1
- Barchart — Hot Penny Stocks on The Move
Disclaimer: This page is speculative opinion and independent commentary, not financial advice, a recommendation, a solicitation, or an offer to buy or sell any security. Every price target and scenario shown here is a hypothetical illustration, not a forecast or a guarantee. Quoted prices are point-in-time snapshots, not live quotes, and may be stale. Always do your own research and consult a licensed financial advisor before investing.